Merck KGaA (ETR: MRK) announced that it has entered into a definitive agreement to acquire Silence Therapeutics plc (NASDAQ: SLN), a UK‑headquartered global clinical‑stage biotechnology company pioneering siRNA therapies in areas of high unmet medical need. The all‑cash transaction values Silence at USD 1.1 billion enterprise value and approximately USD 1.3 billion equity value, an 82 % premium to the target’s recent trading levels, and delivers Merck divesiran, a potentially best‑in‑class investigational siRNA therapy set to enter Phase III clinical trials.
Transaction Overview
| Item | Detail |
|---|---|
| Acquirer | Merck KGaA (ETR: MRK), Darmstadt, Germany |
| Target | Silence Therapeutics plc (NASDAQ: SLN), United Kingdom |
| Structure | Definitive agreement; all‑cash acquisition |
| Price per ADS | USD 20.00 in cash (each ADS = 3 ordinary shares) |
| Price per Ordinary Share | USD 6.6667 |
| Enterprise Value | USD 1.1 billion |
| Equity Value | ≈ USD 1.3 billion |
| Premium | 82 % to Silence’s 30‑day VWAP of USD 10.99 (as of 16 Oct 2026 close, last trading day pre‑announcement) |
| Key Asset Acquired | Divesiran – investigational siRNA targeting TMPRSS6 |
| Next Steps | Not disclosed (closing conditions and timeline not specified in announcement) |
Asset Profile & Mechanism of Action – Divesiran
- Molecule: Divesiran, an investigational small interfering RNA (siRNA) therapy described by Merck as potentially best‑in‑class.
- Target: Selectively silences the TMPRSS6 gene, which encodes a regulator of hepcidin, the master hormone controlling systemic iron homeostasis.
- Mechanism: By suppressing TMPRSS6, divesiran increases hepcidin levels, which in turn controls hematocrit levels and potentially reduces the need for frequent therapeutic phlebotomies.
- Disease Context: The mechanism is directed at conditions of iron‑driven erythrocytosis requiring chronic phlebotomy — most notably polycythemia vera, where elevated hematocrit and repeated bloodletting define the current standard of care.
- Development Stage: Phase III‑ready; the drug is set to enter pivotal clinical trials. Trial design and timing were not disclosed.
Strategic Rationale & Market Impact
- siRNA Platform Acquisition: The deal gives Merck KGaA — the German science and technology group distinct from U.S.-based Merck & Co. (branded EMD in the U.S. and Canada) — a foothold in RNA interference therapeutics, adding Silence’s proprietary siRNA design and delivery expertise to its pipeline.
- Late‑Stage, Near‑Term Value: With divesiran already positioned for Phase III entry, the acquisition delivers a de‑risked, clinically validated asset rather than an early‑stage platform bet alone.
- Unmet Need in Hematology: Patients with elevated hematocrit dependent on frequent therapeutic phlebotomies face substantial quality‑of‑life burden; a subcutaneously administered gene‑silencing approach that controls hematocrit at the source addresses a differentiated need versus chronic bloodletting.
- Premium Signals Conviction: The 82 % premium to the 30‑day VWAP — lifting ADS holders from USD 10.99 to USD 20.00 — underscores competitive tension for late‑stage siRNA assets and Merck’s confidence in divesiran’s best‑in‑class potential.
- Pipeline Depth Beyond Divesiran: Merck also acquires Silence’s broader siRNA research platform and pipeline; specific additional programs were not disclosed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the proposed acquisition of Silence Therapeutics by Merck KGaA, the completion of the transaction, and the clinical development and commercial potential of divesiran. The transaction remains subject to customary conditions, and divesiran is investigational — no regulatory authority has approved it for any indication. Actual outcomes may differ materially due to deal completion risk, clinical trial results, and competitive dynamics.-Fineline Info & Tech
